Butalamine | CAS#22131-35-7 | vasodilator

MedKoo Cat#: 598166 | Name: Butalamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Butalamine is a vasodilator (peripheral) with local anesthetic effects. Butalamine has been shown to inhibit state 3 respiration and decrease ADP/O in rat liver.

Chemical Structure

Butalamine

CAS#22131-35-7 (free base)

Theoretical Analysis

MedKoo Cat#: 598166

Name: Butalamine

CAS#: 22131-35-7 (free base)

Chemical Formula: C18H28N4O

Exact Mass: 316.2263

Molecular Weight: 316.44

Elemental Analysis: C, 68.32; H, 8.92; N, 17.71; O, 5.06

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

22131-35-7 (free base) 56974-46-0 (HCl)

Synonym

Butalamine; Butalamina;

IUPAC/Chemical Name

N1,N1-dibutyl-N2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethane-1,2-diamine

InChi Key

VYWQZAARVNRSTR-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H28N4O/c1-3-5-13-22(14-6-4-2)15-12-19-18-20-17(21-23-18)16-10-8-7-9-11-16/h7-11H,3-6,12-15H2,1-2H3,(H,19,20,21)

SMILES Code

CCCCN(CCNC1=NC(C2=CC=CC=C2)=NO1)CCCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 316.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tine J, Junien JL. Effects of butalamine on oxydative phosphorylations in the rat liver. Arzneimittelforschung. 1976;26(9):1677-80. PubMed PMID: 826262. 2: Morgon A. [Test of butalamine in labyrinth diseases]. JFORL J Fr Otorhinolaryngol Audiophonol Chir Maxillofac. 1976 May;25(5):395-8. French. PubMed PMID: 133207. 3: Traissac L. [Clinical trial of butalamine]. Rev Laryngol Otol Rhinol (Bord). 1973 Sep-Oct;94(9):465-72. French. PubMed PMID: 4603409. 4: Coupar IM, Hedges A, Metcalfe HL, Turner P. Effect of aminophylline, butalamine and imolamine on human isolated smooth muscle. J Pharm Pharmacol. 1969 Jul;21(7):474-5. PubMed PMID: 4390076. 5: Zeitler E. [Xenon-133 muscle clearance before and after butalamine hydrochloride. Results of a double blind test]. Fortschr Med. 1976 Dec 2;94(34):2055-8. German. PubMed PMID: 826469. 6: Sterne J. [Prolonged treatment of obliterantive arteritis with butalamine. Follow up study of 42 cases during more than 1 year of rheographic control]. Rev Clin Esp. 1979 Oct 31;155(2):123-6. Spanish. PubMed PMID: 119287. 7: Sterne J. [Butalamine hydrochloride. A new vasoactive substance]. Fortschr Med. 1976 Apr 15;94(11):657-9. German. PubMed PMID: 823083. 8: Seboldt H. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride]. Fortschr Med. 1980 Feb 21;98(7):257-60. German. PubMed PMID: 6767648. 9: Zmigrodzka K. [Surheme (Butalamine) in the treatment of vertigo]. Otolaryngol Pol. 1976;30(3):227-33. Polish. PubMed PMID: 823509. 10: Kling H. [Drug therapy of chronic arterial occlusive diseases of the lower extremities with butalamine-HCl]. Fortschr Med. 1979 May 17;97(19):926-8. German. PubMed PMID: 109382. 11: Bopp J. [Therapy of arterial-circulation disorders in the legs. Muscle-ergometric studies under the effects of butalamine hydrochloride in a double-blind trial]. Fortschr Med. 1976 Apr 22;94(12):725-7. German. PubMed PMID: 823084. 12: Belousov IuB, Savenkov PM, Sidel'man AA, Parfenov AS, Savenkov MP. [Pharmacotherapy of peripheral arteriosclerosis]. Kardiologiia. 1978 Aug;18(8):36-43. Russian. PubMed PMID: 99596.